Benzinga·2025-11-03 15:29Core Insights - BioNTech SE reported a third-quarter per-share loss of 14 cents, a significant decline from earnings of 81 cents a year ago, and missed the consensus earnings estimate of 75 cents per share [1] - The company achieved sales of $1.78 billion, exceeding the consensus of $1.19 billion, primarily driven by collaboration revenues with Bristol-Myers Squibb [2] Financial Performance - R&D expenses totaled 564.8 million euros, slightly up from 550.3 million euros a year ago [3] - SG&A expenses were 148.5 million euros, down from 150.5 million euros, attributed to lower external costs [3] - Cash and cash equivalents, plus security investments, amounted to 16.71 billion euros [3] Future Guidance - BioNTech raised its fiscal year 2025 revenue guidance from 1.7 billion-2.2 billion euros to 2.6 billion-2.8 billion euros, reflecting stable pricing and market share for COVID-19 vaccines [4] - The company anticipates inventory write-downs and other charges to be approximately 15% of its gross profit from COVID-19 vaccine sales [5] Strategic Focus - The CFO emphasized the strategic value of collaborations, particularly the $1.5 billion received from Bristol-Myers Squibb, and highlighted a commitment to optimizing costs while focusing on R&D and scaling operations in oncology [6] - BioNTech plans to lower expense guidance for R&D, SG&A, and capital expenditures for the 2025 financial year [6] Market Reaction - BioNTech shares were up 0.34% at $104.26 at the time of publication [7]